October 3, 2022 10:37 AM EDT
News Briefing

No­vo Nordisk touts an­oth­er once-week­ly in­sulin win; Mere­o's board bat­tle heats up again

Kyle LaHucik

Senior Reporter

No­vo Nordisk has com­plet­ed the post­ing of topline re­sults across its six Phase II­Ia clin­i­cal tri­als in the ON­WARDS pro­gram, round­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

With Sam Alt­man’s help, Retro Bio­sciences eyes $1B to ex­tend lifes­pan by 10 years

The cru­cial obe­si­ty da­ta to watch for this year

Up­com­ing PDU­FA dates may be en­snared by Trump's pause at HHS, an­a­lyst says

Chi­na's biotech boom is threat­en­ing US drug­mak­er­s' dom­i­nance

No­vo Nordisk’s amy­cretin prompts 22% weight loss in ear­ly obe­si­ty tri­al

sponsored

Fu­el­ing More Break­throughs: Man­u­fac­tur­ing In­no­va­tion to Ex­pand Gene Ther­a­py’s Reach

A service from the Financial Times